Dsm-firmenich Ag · EURONEXT:DSFIR
Dsm-firmenich — Q1 2024 Earnings Presentation
13 slides from Dsm-firmenich's earnings presentation, May 2, 2024
Slide 1: Presentation to Investors – Q1 2024 trading update
Presentation to Investors Q1 2024 trading update May 2, 2024
Slide 2: Highlights Q1 2024
Highlights Q1 2024 Strong performance in Perfumery & Beauty on good demand development Good performance in Taste, Texture & Health underpinned by market recovery Health, Nutrition & Care was soft, with improving momentum by end of quarter Animal Nutrition & Health weak, in anticipation of hi
Slide 3: Q1 2024 Group financial highlights
Q1 2024 Group financial highlights Key financials Actual Pro forma % in €m Q1 2024 Q1 2023¹ Change Volumes increased 3%, offset by lower prices which reflect lower Sales 3,071 3,122 (2) input costs, with good organic sales growth in Perfumery & Beauty Organic sales growth (%) 0 and Taste, Texture
Slide 4: Q1 2024 Perfumery & Beauty
Q1 2024 Perfumery & Beauty Key financials Actual Pro forma % Perfumery & Beauty delivered organic sales growth of 2%, with in €m Q1 2024 Q1 2023¹ Change 4% higher volumes (including a 2% negative effect from the Sales 986 972 1 Pinova plant closure), offset by 2% lower price, reflecting lower Orga
Slide 5: Q1 2024 Taste, Texture & Health
Q1 2024 Taste, Texture & Health Key financials Actual Pro forma % Taste, Texture & Health delivered strong organic growth on in €m Q1 2024 Q1 2023¹ Change improved end-market momentum with the destocking effects Sales 798 772 3 fading Organic sales growth (%) 6 Adj. EBITDA 150 152 (1) Volumes we
Slide 6: Q1 2024 Health, Nutrition & Care
Q1 2024 Health, Nutrition & Care Key financials Actual Pro forma % Health, Nutrition & Care organic sales were down 9% (-6% in €m Q1 2024 Q1 2023¹ Change volumes, -3% price) driven by the vitamin effect Sales 526 582 (10) Organic sales growth (%) (9) The business saw ongoing customer destocking
Slide 7: Q1 2024 Animal Nutrition & Health
Q1 2024 Animal Nutrition & Health Key financials Actual Pro forma % Animal Nutrition & Health continued to be impacted by very low in €m Q1 2024 Q1 2023¹ Change vitamin prices and weak demand for straight vitamins Sales 746 785 (5) Organic sales growth (%) (3) Together with delivering on the vit
Slide 8: Outlook for FY 2024 unchanged
Outlook for FY 2024 unchanged 2024 ‘housekeeping’ • D&A – around €235m/quarter • The company estimates for FY 2024 an • PPA adjustments - around €290m/year Adjusted EBITDA of at least €1.9 billion, which • Core Finex - around €35m/quarter includes a €200 million step-up in Adjusted EBITDA from a com
Slide 9: Decisive actions addressing challenging environment
Decisive actions addressing challenging environment Strategic review Macro Micro Strong future ahead across segments Own actions to Operating in a tough Strengthen Reflected in our improve short-term environment portfolio mid-term targets performance • Weakness in China • Acceleration of integration
Slide 10: OTC Markets Group Welcomes DSM-Firmenich AG to OTCQX
ADR program – OTCQX® Best Market1 • Deutsche Bank has been appointed as depositary bank for the sponsored American Depositary Receipt program of DSM-Firmenich AG • As of April 4, 2024, DSM-Firmenich AG (Euronext Amsterdam: DSFIR; OTCQX: DSFIY, Ratio ORD/DR 1:10) is trading OTCQX® Best Market • To qu
Slide 11: Capital Markets Day Paris June 3, 2024
Capital Markets Day Paris June 3, 2024 • Two years after announcing the merger, we are returning to Paris — this time, for the first Capital Markets Day of dsm- firmenich. • Our CMD will focus on how we will drive progress as innovators in nutrition, health, and beauty. • This event will be an excel
Slide 12: Forward-looking statements disclaimer
This presentation contains forward-looking statements with respect to dsm-firmenich’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions
Slide 13: We bring progress to life
We bring progress to life™ dsm-firmenich ese